FDA's own reviewers say no: seven peptides head to an advisory vote on the 503A compounding list

This is a different list from the one in the June story. The June action concerned the 503B bulks list — what larger outsourcing facilities may compound from bulk — and centered on GLP-1s. This meeting is about the 503A list, which governs patient-specific compounding by a state-licensed pharmacy or physician, and it concerns non-GLP-1 peptides that have circulated in the wellness and "research chemical" market for years.

Two things are worth getting right about the mechanics. First, the committee is advisory. It makes non-binding recommendations; FDA generally follows them but is not required to, and the agency has said it will not issue a final determination until after the committee process and until its own reviews are finalized. Second, the standard is a balancing test. Under the 2019 final rule that set the criteria, FDA weighs four things for each substance: physical and chemical characterization, safety, the evidence of effectiveness (or lack of it), and the history of use in compounding. No single factor decides it; the agency balances them substance by substance.

The briefing package states the agency's proposal plainly for each substance. In FDA's words, it "is proposing that" each of the following "NOT be included on the 503A Bulks List":

That is the agency's read before the committee has spoken. The committee could agree, push back, or split — that is the point of the meeting — but the reviewers' starting position is a uniform no.

The BPC-157 document is the clearest worked example, and it is the peptide most of our readers ask about. FDA's conclusion is that "a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed on" the list. On effectiveness, the review finds "a lack of evidence to support the effectiveness of BPC-157" for ulcerative colitis, noting there has been "a single, small trial" whose interpretation "is limited by the lack of details provided in the meeting abstract and the exploratory nature of the study," and no studies at all administering BPC-157 by the oral, subcutaneous, nasal, or transdermal routes people actually use. On safety, it finds "insufficient clinical safety information to characterize the safety profile," with no human studies via those proposed routes and only short rectal-enema studies with limited safety monitoring — a problem for what would be long-term use.

TB-500 lands the same way: FDA writes that "a balancing of the criteria weighs against TB-500 (free base) and TB-500 acetate being placed on" the list, again citing "a lack of evidence to evaluate the effectiveness" of the substance. Across the seven, the recurring themes are the same three the balancing test is built around — incomplete characterization of what the compounded substance actually is (including impurities), thin or absent human safety data for the routes of use, and effectiveness evidence that is preliminary at best. None of this says the molecules are proven dangerous; it says the evidence needed to put them on a compounding list is not there.

There is an unusual procedural detail in the briefing package. The original nominations for these substances — filed years ago by LDT Health Solutions on behalf of the International Peptide Society and by Wells Pharmacy Network — were withdrawn by the nominators. FDA is proceeding to present all seven to the committee anyway. In other words, the agency chose to put these peptides through a public advisory review even after the parties who asked for them backed out. That is a signal in itself about how FDA wants the 503A status of this whole category settled on the record, rather than left ambiguous.

The June story and this one are two fronts in the same broader tightening of the compounding channel. There, FDA proposed to strip semaglutide, tirzepatide, and liraglutide off the 503B bulks list and sent warning letters over how compounded GLP-1s were marketed. Here, the agency's reviewers are recommending against seating a set of non-GLP-1 peptides on the 503A list in the first place. Different lists, different molecules, different legal pathways — but the same direction of travel: the regulatory door to compounding these substances from bulk is narrowing, not widening.

In the near term, nothing changes on July 24. A committee recommendation — whichever way it goes — does not by itself alter the law. FDA still has to weigh the committee's advice, finalize its reviews, and issue a determination, and there is no fixed timeline for that step. Substances in this "not yet on the list, not clearly off it" posture have sat in that gray zone for a long time.

What the meeting does change is clarity about where FDA stands. If you are using a compounded BPC-157, TB-500, or any of the others named here, the agency's published view is now on the record: it does not think the effectiveness and safety evidence supports adding them to the 503A list. That is worth knowing when a provider or clinic frames one of these as a settled, well-characterized therapy. The practical questions to ask are the same ones our coverage keeps coming back to: which entity actually compounds the product, under which pathway, and what independent evidence — not marketing copy — supports the specific use being proposed. For how state rules layer on top of all this, see our guide to state-by-state access.

The committee has now voted. See the full vote record and what it changes.